Cargando…
Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
SUMMARY: Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849471/ https://www.ncbi.nlm.nih.gov/pubmed/33431709 http://dx.doi.org/10.1530/EDM-20-0174 |
_version_ | 1783645308955131904 |
---|---|
author | Sotiridou, Ellada Hoermann, Henrike Aftab, Sommayya Dastamani, Antonia Thimm, Eva Doodson, Louise Batzios, Spyros Kummer, Sebastian Shah, Pratik |
author_facet | Sotiridou, Ellada Hoermann, Henrike Aftab, Sommayya Dastamani, Antonia Thimm, Eva Doodson, Louise Batzios, Spyros Kummer, Sebastian Shah, Pratik |
author_sort | Sotiridou, Ellada |
collection | PubMed |
description | SUMMARY: Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction were diagnosed with hyperinsulinaemic hypoglycaemia in the neonatal period. Both siblings were successfully treated with diazoxide/chlorthiazide and treatment was gradually weaned and stopped after 8 and 6 months of age respectively. The third patient presented with a neonatal liver failure with mild cholestasis, coagulopathy, fundus haemorrhages, vitamin A and E deficiency and hyperinsulinaemic hypoglycaemia. He maintained euglycaemia on high dose diazoxide (5–12 mg/kg/day) but developed pulmonary hypertension at 12 weeks of age. After discontinuation of diazoxide, he continued maintaining his blood glucose (BG) within the normal range. Although histological abnormalities of the pancreas including beta-cell hyperplasia are well documented, the exact mechanism of excessive insulin secretion in TT1 is not well understood. It may be related to the accumulation of toxic metabolites in the target organs including pancreas. Therefore, in patients with TT1 and persistent hypoglycaemia beyond the recovery of the acute liver failure, it is important to exclude hyperinsulinism which is usually transient and can be successfully treated with diazoxide and chlorothiazide. Further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. LEARNING POINTS: Every child with TT1 should be monitored for signs and symptoms of hypoglycaemia and screened for HH at the time of real hypoglycaemia. If hypoglycaemic episodes persist even after improvement of liver function, hyperinsulinism should be suspected. Treatment with diazoxide is effective, however, children need to be monitored closely for possible side effects. The pathophysiological mechanism of hyperinsulinism in children with TT1 is not elucidated yet and further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. |
format | Online Article Text |
id | pubmed-7849471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-78494712021-02-03 Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 Sotiridou, Ellada Hoermann, Henrike Aftab, Sommayya Dastamani, Antonia Thimm, Eva Doodson, Louise Batzios, Spyros Kummer, Sebastian Shah, Pratik Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease SUMMARY: Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction were diagnosed with hyperinsulinaemic hypoglycaemia in the neonatal period. Both siblings were successfully treated with diazoxide/chlorthiazide and treatment was gradually weaned and stopped after 8 and 6 months of age respectively. The third patient presented with a neonatal liver failure with mild cholestasis, coagulopathy, fundus haemorrhages, vitamin A and E deficiency and hyperinsulinaemic hypoglycaemia. He maintained euglycaemia on high dose diazoxide (5–12 mg/kg/day) but developed pulmonary hypertension at 12 weeks of age. After discontinuation of diazoxide, he continued maintaining his blood glucose (BG) within the normal range. Although histological abnormalities of the pancreas including beta-cell hyperplasia are well documented, the exact mechanism of excessive insulin secretion in TT1 is not well understood. It may be related to the accumulation of toxic metabolites in the target organs including pancreas. Therefore, in patients with TT1 and persistent hypoglycaemia beyond the recovery of the acute liver failure, it is important to exclude hyperinsulinism which is usually transient and can be successfully treated with diazoxide and chlorothiazide. Further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. LEARNING POINTS: Every child with TT1 should be monitored for signs and symptoms of hypoglycaemia and screened for HH at the time of real hypoglycaemia. If hypoglycaemic episodes persist even after improvement of liver function, hyperinsulinism should be suspected. Treatment with diazoxide is effective, however, children need to be monitored closely for possible side effects. The pathophysiological mechanism of hyperinsulinism in children with TT1 is not elucidated yet and further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. Bioscientifica Ltd 2021-01-11 /pmc/articles/PMC7849471/ /pubmed/33431709 http://dx.doi.org/10.1530/EDM-20-0174 Text en © 2021 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (http://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Unique/Unexpected Symptoms or Presentations of a Disease Sotiridou, Ellada Hoermann, Henrike Aftab, Sommayya Dastamani, Antonia Thimm, Eva Doodson, Louise Batzios, Spyros Kummer, Sebastian Shah, Pratik Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 |
title | Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 |
title_full | Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 |
title_fullStr | Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 |
title_full_unstemmed | Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 |
title_short | Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 |
title_sort | diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1 |
topic | Unique/Unexpected Symptoms or Presentations of a Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849471/ https://www.ncbi.nlm.nih.gov/pubmed/33431709 http://dx.doi.org/10.1530/EDM-20-0174 |
work_keys_str_mv | AT sotiridouellada diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT hoermannhenrike diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT aftabsommayya diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT dastamaniantonia diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT thimmeva diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT doodsonlouise diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT batziosspyros diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT kummersebastian diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 AT shahpratik diazoxideresponsivehyperinsulinaemichypoglycaemiaintyrosinaemiatype1 |